Trial Profile
A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2019
Price :
$35
*
At a glance
- Drugs Belotecan (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chong Kun Dang
- 25 Dec 2018 Status changed from recruiting to completed.
- 26 Sep 2018 Primary endpoint (Objectives Response Rate) has been met, according to results presented at the 19th World Conference on Lung Cancer.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer